IARS1 and melanoma: To investigate whether SEC62 expression differed in various subtypes of melanocytic tumors, Sec62-IRS was compared between melanoma (MM; n = 93), melanoma metastases (MET; n = 28), Spitz nevi (SN; n = 29), blue nevi (BN; n = 21), and congenital nevi (CN; n = 38).